China Tissue Diagnostics Market Size & Outlook, 2026-2033
The tissue diagnostics market in China is expected to reach a projected revenue of US$ 1,246.8 million by 2033. A compound annual growth rate of 10% is expected of China tissue diagnostics market from 2026 to 2033.
The China tissue diagnostics market generated a revenue of USD 591.0 million in 2025 and is expected to reach USD 1,246.8 million by 2033.
The China market is expected to grow at a CAGR of 10% from 2026 to 2033.
In terms of segment, hospitals was the largest revenue generating end use in 2025.
CRO is the most lucrative end use segment registering the fastest growth during the forecast period.
Tissue diagnostics market data book summary
Market revenue in 2025
USD 591.0 million
Market revenue in 2033
USD 1,246.8 million
Growth rate
10% (CAGR from 2026 to 2033)
Largest segment
Hospitals
Fastest growing segment
CRO
Historical data
2021 - 2024
Base year
2025
Forecast period
2026 - 2033
Quantitative units
Revenue in USD million
Market segmentation
Diagnostic center, Hospitals, CRO, Pharmaceutical Organizations
Key market players worldwide
Roche Holding AG ADR, Abbott Laboratories, Thermo Fisher Scientific Inc, Siemens AG, Danaher Corp, BioMerieux SA, Qiagen NV, BD, Merck KGaA, GE Aerospace, Agilent Technologies Inc, Biogenex, Cell Signaling Technology, Bio SB, DiaGenic
Other key industry trends
In terms of revenue, China accounted for 6.3% of the global tissue diagnostics market in 2025.
Country-wise, U.S. is expected to lead the global market in terms of revenue in 2033.
In Asia Pacific, China tissue diagnostics market is projected to lead the regional market in terms of revenue in 2033.
India is the fastest growing regional market in Asia Pacific and is projected to reach USD 734.1 million by 2033.
Supportive government regulations and investments by private organizations have led to rapid increase in cancer research in this country. Rapid increase in nanoscience R&D in China has attracted worldwide attention, thereby boosting revenue generation.
High incidence of cervical cancer remains a major problem in China, which provides lucrative growth opportunities for diagnostics devices, such as tissue diagnostics. In 2014, cell staining techniques was developed to detect cervical cancer, which helped distinguish between neoplastic and normal cells, based on morphology & color retained.
In 2015, IHC assay was performed on BARF using V600E (VE1) mouse monoclonal primary antibody on a Ventana slide strainer to detect BARF mutation in tumor patients in China. BARF is considered as a potential diagnostic and prognostic marker for cancer detection in clinical diagnostics.
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to Tissue Diagnostics Market Outlook will help companies and investors design strategic landscapes.
Hospitals was the largest segment with a revenue share of 40.9% in 2025.
Horizon Databook has segmented the China tissue diagnostics market based on diagnostic center, hospitals, cro, pharmaceutical organizations covering the revenue growth of each sub-segment from 2021 to 2033.
Supportive government regulations and investments by private organizations have led to rapid increase in cancer research in this country. Rapid increase in nanoscience R&D in China has attracted worldwide attention, thereby boosting revenue generation.
High incidence of cervical cancer remains a major problem in China, which provides lucrative growth opportunities for diagnostics devices, such as tissue diagnostics. In 2014, cell staining techniques was developed to detect cervical cancer, which helped distinguish between neoplastic and normal cells, based on morphology & color retained.
In 2015, IHC assay was performed on BARF using V600E (VE1) mouse monoclonal primary antibody on a Ventana slide strainer to detect BARF mutation in tumor patients in China. BARF is considered as a potential diagnostic and prognostic marker for cancer detection in clinical diagnostics.
China Tissue Diagnostics Market End use Outlook (Revenue, USD Million , 2021-2033)
Diagnostic center
Hospitals
CRO
Pharmaceutical Organizations
China Tissue Diagnostics Market Technology Outlook (Revenue, USD Million , 2021-2033)
Immunohistochemistry
In situ Hybridization
Primary & Special Staining
Digital Pathology and Workflow
Anatomic Pathology
Molecular Pathology
China Tissue Diagnostics Market Application Outlook (Revenue, USD Million , 2021-2033)
Non Small Cell Lung Cancer
Other Cancers
Gastric Cancer
Breast Cancer
Prostate Cancer
China Tissue Diagnostics Market Modality Outlook (Revenue, USD Million , 2021-2033)
Pharma / CRO / Research market
Clinical market
Reasons to subscribe to Tissue Diagnostics Market Outlook databook
Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of Tissue Diagnostics Market Outlook databook
Our clientele includes a mix of Tissue Diagnostics Market Outlook companies, investment firms, advisory firms & academic institutions.
30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of country-level data and insights on the China Tissue Diagnostics Market Outlook, including forecasts for subscribers. This country databook contains high-level insights into China Tissue Diagnostics Market Outlook from 2021 to 2033, including revenue numbers, major trends, and company profiles.